On October 14, Johnson & Johnson announced its 2025 Q3 results, the third quarter.Revenue of $23.993 billion,An increase of 6.8% year-over-year. Combining the performance of the first two quarters, Johnson & Johnson's total revenue in the first nine months of this year has reached $69.629 billion (+5.0%), with innovative pharmaceuticals and medical technology generating $44.638 billion (+4.7%) and $23.669 billion (+5.6%), respectively.Johnson & Johnson's innovative pharmaceuticals business mainly focuses on oncology, autoimmune diseases, neuroscience,Pulmonary Hypertension,Infection, Cardiovascular and Metabolic Fields, Six Key SegmentsIn the first nine monthsGenerate Revenue Respectively$18.519 billion (+21.2%)、118.68Billion USD (-12.7%), 57.22Billion USD (+7.2%), 32.53Billion USD (+2.0%), 24.34Billion USD (-7.2%), 28.42Billion USD (+9.1%)。The oncology business has become the main driver of Johnson & Johnson's performance,Growth was primarily driven by strong performance from products such as Darzalex (daratumumab), Erleada (apalutamide), and Carvykti (cilta-cel).. Among them,Carvykti Generated $1.332 Billion in Revenue in the First Nine Months, Doubling from $629 Million in the Same Period Last Year。Autoimmune Business: Impacted by Stelara (Ustekinumab) Losing Market Exclusivity, Performance in This Segment Continues to Decline.The first nine months,Stelara's sales have dropped to $4.848 billion (-39.5%). Tremfya (guselkumab) maintained strong growth, with revenue of $3.566 billion (+31.0%) in the first three quarters, and its annual sales are expected to exceed $5 billion.In the field of neuroscience, Spravato (esketamine nasal spray) has shown impressive results.The First Nine MonthsSales reached $1.193 billion (+53.0%). Simultaneous coverage for treatment-resistant depression and major depressive disorder accelerated.The market expansion speed of Spravato.Looking ahead to the full year, Johnson & Johnson has once again raised its revenue forecast, expecting full-year sales to increase by 4.8%-5.3% to $93 billion-$93.4 billion.On the same day of announcing the financial results, Johnson & Johnson alsoAnnouncedSpin off orthopedics business and establish an independent companyThe decision,The spin-off company will be named DePuy Synthes., while Namal Nawana will serve as its Global President.According to a Johnson & Johnson press release, its orthopedics business is expected to generate approximately $9.2 billion in revenue in 2024.Copyright © 2025 PHARMCUBE. All Rights Reserved. Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
